GLP-1 receptor agonists × all-cause mortality

TrialThe New England journal of medicine2016

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Steven P Marso et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 9,340 people · 2016

Randomised comparison

Reduced deaths

−15%−26% to −3%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.85, 95% CI 0.74–0.97 · the paper's word: All-cause mortality

One number in the abstract

the abstract, start to end

group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02).

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.850.74–0.97
GLP-1 receptor agonistsAll-cause mortality

GLP-1 receptor agonists × all-cause mortalityhelps?replicated

unlikelylikely
0.880.86 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

3,095 papers cite itlatest 60 shown

2016
2026
this paperpooled ittrialcites it

19 trials

Full record →Abstract, authors, funding and every citing paper · PMID 27295427